US Biosimilars Will Get Regulatory Science Program, Supplement Timeline Changes In Next User Fee Agreement

 
• By Derrick Gingery

Talks are completed, leaving only the generic drug user fee reauthorization negotiations ongoing.

Sign outside of FDA's headquarters in White Oak, MD
The completed BsUFA III agreement includes supplement timeline improvements

More from Biosimilars

More from Products